VIP-targeted cytotoxic nanomedicine for breast cancer
First Online: 12 October 2012 DOI:
Cite this article as: Dagar, A., Kuzmis, A., Rubinstein, I. et al. Drug Deliv. and Transl. Res. (2012) 2: 454. doi:10.1007/s13346-012-0107-x Abstract
Cancer chemotherapy is hampered by serious toxicity to healthy tissues. Conceivably, encapsulation of cytotoxic drugs in actively targeted, biocompatible nanocarriers could overcome this problem. Accordingly, we used sterically stabilized mixed micelles (SSMM) composed of biocompatible and biodegradable phospholipids to solubilize paclitaxel (P), a hydrophobic model cytotoxic drug, and deliver it to breast cancer in rats. To achieve active targeting, the surface of SSMM was grafted with a ligand, human vasoactive intestinal peptide (VIP) that selectively interacts with its cognate receptors overexpressed on breast cancer cells. We found that even in vitro cytotoxicity of P-SSMM-VIP was 2-fold higher that that of free paclitaxel (
p < 0.05). Given the unique attributes of P-SSMM and P-SSMM-VIP, most notable small hydrodynamic diameter (∼15 nm) and stealth properties, biodistribution of paclitaxel was significantly altered. Accumulation of paclitaxel in breast tumor was highest for P-SSMM-VIP, followed by P-SSMM and Cremophor-based paclitaxel (PTX). Importantly, bone marrow accumulation of paclitaxel encapsulated in both SSMM-VIP and SSMM was significantly less than that of PTX. Administration of clinically relevant dose of paclitaxel (5 mg/kg) as P-SSMM-VIP and P-SSMM eradicated carcinogen-induced orthotopic breast cancer in rats, whereas PTX decreased tumor size by only 45 %. In addition, a 5-fold lower dose (1 mg/kg) of paclitaxel in actively targeted P-SSMM-VIP was associated with ∼80 % reduction in tumor size while the response to PTX and P-SSMM was significantly less. Hypotension was not observed when VIP was grafted onto SSMM. Based on our findings, we propose further development of effective and safe VIP-grafted phospholipid micelle nanomedicines of anti-cancer drugs for targeted treatment of solid tumors in humans. Keywords Phospholipid mixed micelles Targeted drug delivery Human vasoactive intestinal peptide Breast cancer Paclitaxel MNU-induced breast cancer Electronic supplementary material
The online version of this article (doi:
) contains supplementary material, which is available to authorized users. 10.1007/s13346-012-0107-x References
Singh S, Dash AK. Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges. Crit Rev Ther Drug Carrier Syst. 2009;26(4):333–72.
Lim SB, Banerjee A, Onyuksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J Control Release. 2012.
Banerjee A, Onyuksel H. Human pancreatic polypeptide in a phospholipid-based micellar formulation. Pharm Res. 2012;29(6):1698–711.
Koo OM, Rubinstein I, Onyuksel H. Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis. Pharm Res. 2011;28(4):776–87.
Onyuksel H, Mohanty PS, Rubinstein I. VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer. Int J Pharm. 2009;365(1–2):157–61.
Cesur H, Rubinstein I, Pai A, Onyuksel H. Self-associated indisulam in phospholipid-based nanomicelles: a potential nanomedicine for cancer. Nanomedicine. 2009;5(2):178–83.
Krishnadas A, Rubinstein I, Önyüksel H. Sterically stabilized phospholipid mixed micelles: in vitro evaluation as a novel carrier for water-insoluble drugs. Pharm Res. 2003;20(2):297–302.
Ashok B, Arleth L, Hjelm RP, Rubinstein I, Onyuksel H. In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: effects of PEG chain length and PC incorporation. J Pharm Sci. 2004;93(10):2476–87.
Kuzmis A, Lim SB, Desai E, Jeon E, Lee BS, Rubinstein I, et al. Micellar nanomedicine of human neuropeptide Y. Nanomedicine. 2011;4(7):464–71.
Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3):136–51.
Wittrup KD, Thurber GM, Schmidt MM, Rhoden JJ. Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol. 2012;503:255–68.
Dagar S, Krishnadas A, Rubinstein I, Blend MJ, Onyuksel H. VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies. J Control Release. 2003;91(1–2):123–33.
Zhang XX, Eden HS, Chen X. Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates. J Control Release. 2012;159(1):2–13
Yu B, Tai HC, Xue W, Lee LJ, Lee RJ. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol. 2010;27(7):286–98.
Reubi JC. In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Ann N Y Acad Sci. 2000;921:1–25.
Ortner A, Wernig K, Kaisler R, Edetsberger M, Hajos F, Kohler G, et al. VPAC receptor mediated tumor cell targeting by protamine based nanoparticles. J Drug Target. 2010;18(6):457–67.
Reubi JC, Laderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res. 2000;60(11):3105–12.
Schulz S, Rocken C, Mawrin C, Weise W, Hollt V, Schulz S. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies. Clin Cancer Res. 2004;10(24):8235–42.
Dagar S, Sekosan M, Rubinstein I, Onyuksel H. Detection of VIP receptors in MNU-induced breast cancer in rats: implications for breast cancer targeting. Breast Cancer Res Treat. 2001;65(1):49–54.
Reubi JC. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J Nucl Med. 1995;36(10):1846–53.
Reubi C, Gugger M, Waser B. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2002;29(7):855–62.
Raderer M, Kurtaran A, Yang Q, Meghdadi S, Vorbeck F, Hejna M, et al. Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer. J Nucl Med. 1998;39(9):1570–5.
Rubinstein I, Soos I, Onyuksel H. Intracellular delivery of VIP-grafted sterically stabilized phospholipid mixed nanomicelles in human breast cancer cells. Chem Biol Interact. 2008;171(2):190–4.
Onyuksel H, Jeon E, Rubinstein I. Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells. Cancer Lett. 2009;274(2):327–30.
Fahrenkrug J, Hannibal J, Tams J, Georg B. Immunohistochemical localization of the VIP1 receptor (VPAC1R) in rat cerebral blood vessels: relation to PACAP and VIP containing nerves. J Cereb Blood Flow Metab. 2000;20(8):1205–14.
Dagar S, Sekosan M, Lee BS, Rubinstein I, Onyuksel H. VIP receptors as molecular targets of breast cancer: implications for targeted imaging and drug delivery. J Control Release. 2001;74(1–3):129–34.
Sou K, Endo T, Takeoka S, Tsuchida E. Poly(ethylene glycol)-modification of the phospholipid vesicles by using the spontaneous incorporation of poly(ethylene glycol)-lipid into the vesicles. Bioconjug Chem. 2000;11(3):372–9.
Seelig J. Titration calorimetry of lipid–peptide interactions. Biochim Biophys Acta. 1997;1331(1):103–16.
Zuidam NJ, de Vruch R., Crommelin D.J.A. Characterization of liposomes. In: Torchilin VP, Weissig V., editors. Liposomes. 2nd ed. Oxford: Oxford University Press; 2003. p. 31.
Moody TW, Jensen RT. Breast cancer VPAC1 receptors. Ann N Y Acad Sci. 2006;1070:436–9.
Moon RC, Constantinou AI. Dietary retinoids and carotenoids in rodent models of mammary tumorigenesis. Breast Cancer Res Treat. 1997;46(2–3):181–9.
Arleth L, Ashok B, Onyuksel H, Thiyagarajan P, Jacob J, Hjelm RP. Detailed structure of hairy mixed micelles formed by phosphatidylcholine and PEGylated phospholipids in aqueous media. Langmuir. 2005;21(8):3279–90.
Couvineau A, Tan YV, Ceraudo E, Lacapere JJ, Murail S, Neumann JM, et al. The human VPAC1 receptor: identification of the N-terminal ectodomain as a major VIP-binding site by photoaffinity labeling and 3D modeling. Ann N Y Acad Sci. 2006;1070:205–9.
Bhunia A, Domadia PN, Bhattacharjya S. Structural and thermodynamic analyses of the interaction between melittin and lipopolysaccharide. Biochim Biophys Acta. 2007;1768(12):3282–91.
Schote U, Ganz P, Fahr A, Seelig J. Interactions of cyclosporines with lipid membranes as studied by solid-state nuclear magnetic resonance spectroscopy and high-sensitivity titration calorimetry. J Pharm Sci. 2002;91(3):856–67.
Hagiwara H, Sunada Y. Mechanism of taxane neurotoxicity. Breast Cancer. 2004;11(1):82–5.
Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm. 2008;69(1):1–9.
Spratlin J, Sawyer MB. Pharmacogenetics of paclitaxel metabolism. Crit Rev Oncol Hematol. 2007;61(3):222–9.
Wang Y, Li X, Wang L, Xu Y, Cheng X, Wei P. Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery. Int J Nanomed. 2011;6:1497–507.
Fetterly GJ, Straubinger RM. Pharmacokinetics of paclitaxel-containing liposomes in rats. AAPS PharmSci. 2003;5(4):E32.
Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 2012;14(2):282–95.
Tsubura A, Lai YC, Miki H, Sasaki T, Uehara N, Yuri T, et al. Review: animal models of N-Methyl-N-nitrosourea-induced mammary cancer and retinal degeneration with special emphasis on therapeutic trials. In Vivo. 2011;25(1):11–22.
Nowfar S, Teplitzky SR, Melancon K, Kiefer TL, Cheng Q, Dwived PD, et al. Tumor prevention by 9-cis-retinoic acid in the N-nitroso-N-methylurea model of mammary carcinogenesis is potentiated by the pineal hormone melatonin. Breast Cancer Res Treat. 2002;72(1):33–43.
Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med. 1994;331(17):1116–21.
Leamon CP. Folate-targeted drug strategies for the treatment of cancer. Curr Opin Investig Drugs. 2008;9(12):1277–86.
Daniels TR, Delgado T, Helguera G, Penichet ML. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol. 2006;121(2):159–76.
Rubinstein I, Ashok B, Tsueshita T, Onyuksel H. All D-VIP mitigates vasodilation elicited by L-VIP, micellar L-VIP and micellar PACAP1-38, but not PACAP1-38, in vivo. Peptides. 2005;26(3):509–15.
Montana M, Ducros C, Verhaeghe P, Terme T, Vanelle P, Rathelot P. Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers. J Chemother. 2011;23(2):59–66.
PubMed Copyright information
© Controlled Release Society 2012